Phase 2 High-Risk Clinical Trials
16 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–16 of 16 trials
Recruiting
Phase 2
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
High-Risk Oral Precancerous Disease
Glenn J. Hanna25 enrolled2 locationsNCT06623110
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Prostate CancerHigh-risk Prostate Cancer
Icahn School of Medicine at Mount Sinai40 enrolled1 locationNCT07027124
Recruiting
Phase 2
ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse
Lymphoma Patients With High-risk of Central Nervous System Relapse
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07481669
Recruiting
Phase 2
Immunoprevention for High-risk Lung Lesions
High-risk Lung Nodules
Robert Samstein59 enrolled1 locationNCT07284485
Recruiting
Phase 2
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD32 enrolled6 locationsNCT05498272
Recruiting
Phase 2
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Hormone Receptor-Positive Breast CancerHigh-risk Breast Cancer
Peking University People's Hospital393 enrolled1 locationNCT06970912
Recruiting
Phase 2
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
Cutaneous Squamous Cell Carcinoma of the Head and NeckClinically Node-Negative (cN0)High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
University of California, Davis24 enrolled1 locationNCT06990737
Recruiting
Phase 2
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
Rectal AdenocarcinomaHigh-Risk CancerMSS
Sixth Affiliated Hospital, Sun Yat-sen University49 enrolled1 locationNCT06908031
Recruiting
Phase 1Phase 2
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd.150 enrolled1 locationNCT05410730
Recruiting
Phase 2
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Prostate CancerProstate CancersProstate Cancer (Adenocarcinoma)+4 more
Cellvax Therapeutics Inc100 enrolled3 locationsNCT06636682
Recruiting
Phase 1Phase 2
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.24 enrolled6 locationsNCT06378242
Recruiting
Phase 1Phase 2
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
High-risk Soft Tissue Sarcoma
Affiliated Hospital to Academy of Military Medical Sciences30 enrolled1 locationNCT01898663
Recruiting
Phase 1Phase 2
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
High-Risk Localized Soft Tissue Sarcoma
Fudan University52 enrolled1 locationNCT05839275
Recruiting
Phase 1Phase 2
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
High-Risk Localized Soft Tissue Sarcoma
Fudan University52 enrolled1 locationNCT05774275
Recruiting
Phase 2
Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse
High-risk acute leukemia patients
Huisheng Ai40 enrolled1 locationACTRN12608000129381